Metacrine’s lead drug Fast Track’d for NASH

The FDA designates Metacrine’s (MTCR) lead program, MET409 for Fast Track review for the treatment of non-alcoholic steatohepatitis (NASH).

MET409 targets farnesoid X receptor (FXR) a protein which plays a key role in modulating said diseases.

Recently, the company filed for $100M IPO.

https://seekingalpha.com/news/3608760-metacrine-lead-drug-fast-trackd-for-nash